Stock 2315 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

Biotechnology & Medical Research

End-of-day quote Hong Kong S.E.
Other stock markets
 06:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
9.76 CNY +0.31% Intraday chart for Biocytogen Pharmaceuticals (Beijing) Co., Ltd. +2.09% -18.53%
May. 06 Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies CI
Apr. 26 Biocytogen Pharmaceuticals' Loss Narrows in 2023 MT

Business Summary

Biocytogen Pharmaceuticals Beijing Co Ltd is a company mainly engaged in drug development business and preclinical research. The Company operates its business through five segments. The Gene-Editing services segment provides the customized gene-editing services based on animals as well as cells. The Pre-clinical Pharmacology and Efficacy Evaluation segment provides preclinical pharmacology services for the evaluation of drug efficacy and toxicity. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment utilises its antibody discovery platforms to identify antibodies which have the potential to become drug candidates. The Innovative Drugs Development segment is engaged in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics. The Company also conducts its business through the Other segment.

Number of employees: 1,066

Sales per Business

HKD in Million2022Weight2023Weight Delta
Animal Models Selling
38.1 %
197 31.7 % 301 38.1 % +53.09%
Pre-clinical Pharmacology and Efficacy Evaluation
27.0 %
205 33.0 % 214 27.0 % +4.37%
Antibody Development
24.5 %
148 23.8 % 194 24.5 % +31.70%
Gene-editing
10.4 %
71 11.4 % 82 10.4 % +15.64%
Others
0.1 %
1 0.1 % 1 0.1 % -6.07%

Sales per region

HKD in Million2022Weight2023Weight Delta
China
43.0 %
335 53.9 % 341 43.0 % +1.92%
United States
42.0 %
208 33.5 % 333 42.0 % +59.88%
Others
14.9 %
78 12.6 % 118 14.9 % +51.60%

Managers

Managers TitleAgeSince
Yue Lei Shen CEO
 Chief Executive Officer - 09-11-12
Liu Bin DFI
 Director of Finance/CFO - 20-01-04
Sabrina Wang COO
 Chief Operating Officer - 19-09-30
Yi Yang CTO
 Chief Tech/Sci/R&D Officer - 16-10-31
Jia Wei Yao BRD
 Director/Board Member 41 12-05-31
Zhi Hong Li PRN
 Corporate Officer/Principal - 19-02-28
Chao She Guo PRN
 Corporate Officer/Principal - 13-09-30
Yan Zhu HRO
 Human Resources Officer 60 11-11-30
Wai Ching Au SEC
 Corporate Secretary - -
Yong Liang Wang SEC
 Corporate Secretary 59 -

Members of the board

Members of the board TitleAgeSince
Feng Mao Hua BRD
 Director/Board Member 56 21-06-30
Yi Liang Wei BRD
 Director/Board Member 53 -
Xiao Yan Liang BRD
 Director/Board Member 58 20-11-30
Yue Lei Shen CEO
 Chief Executive Officer - 09-11-12
Jian Ni BRD
 Director/Board Member - -
Hai Chao Zhang BRD
 Director/Board Member - -
Yan Li BRD
 Director/Board Member - -
Chun Li Sun BRD
 Director/Board Member - -
Lei Di Zhang
44 -
Jia Wei Yao BRD
 Director/Board Member 41 12-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 288,616,500 0 0 16.99 %
Stock B 1 110,781,920 67,839,140 ( 61.24 %) 0

Shareholders

NameEquities%Valuation
Shanghai Bioveda Investment Management Consulting Co. Ltd.
18.32 %
20,291,400 18.32 % 23 M ¥
NameEquities%Valuation
SDIC Venture Capital Co. Ltd.
25.27 %
72,937,440 25.27 % 81 M ¥
Yue Lei Shen
22.26 %
64,235,700 22.26 % 72 M ¥
China Merchant Bank International Capital Mgmt Shenzhen Ltd.
17.73 %
51,171,440 17.73 % 57 M ¥
Ningbo Huatai Investment Co., Ltd.
10.67 %
30,804,120 10.67 % 34 M ¥
Jian Ni
10.05 %
29,004,840 10.05 % 32 M ¥
China Life Private Equity Investment Co. Ltd.
8.149 %
23,519,160 8.149 % 26 M ¥

Company contact information

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Room 1207, Building 3 88 Kechuang 6th Street

100176, Beijing

+86 10 5696 7680

http://www.bbctg.com.cn
address Biocytogen Pharmaceuticals (Beijing) Co., Ltd.(2315)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
9.051 CNY
Average target price
14.21 CNY
Spread / Average Target
+57.04%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. Stock Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
-18.53% 498M
MODERNA, INC. Stock Moderna, Inc.
+64.92% 62.59B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.85% 41.18B
LONZA GROUP AG Stock Lonza Group AG
+44.76% 40.29B
CELLTRION, INC. Stock Celltrion, Inc.
-8.93% 27.9B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.05% 26.21B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.96% 19.09B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.21% 13.08B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.74% 12.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.42% 12.05B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 2315 Stock
  4. Company Biocytogen Pharmaceuticals (Beijing) Co., Ltd.